Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of temozolomide on tumor mutation burden and microsatellite instability in melanoma cells.

The Journal of dermatology - 1 Mar 2024

Sawada Masahide, Hida Tokimasa, Kamiya Takafumi, Minowa Tomoyuki, Kato Junji, Okura Masae, Idogawa Masashi, Tokino Takashi, Uhara Hisashi

Abstract excerpt

The efficacy of combination therapy with an immune checkpoint inhibitor (ICI) and cytotoxic chemotherapeutic agents has been investigated in cancer, including melanoma. Before ICIs were introduced, dacarbazine or temozolomide (TMZ) were used to treat melanoma. Several studies using glioma or colorectal cancer cells showed that TMZ can increase the tumor mutation burden (TMB) and induce mismatch repair (MMR)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to DNA Mismatch Repair

Share to Melanoma

Share to Microsatellite Instability

Share to Neoplastic Syndromes, Hereditary

Share to Temozolomide

Source

Identifiers

PMID: 37658676
DOI: 10.1111/1346-8138.16925

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of temozolomide on tumor mutation burden and microsatellite instability in melanoma cells.PMID 37658676Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

The immune response-related genomic alterations in patients with malignant melanoma.Semantic proximity Read ↗

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read ↗

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.Semantic proximity Read ↗

Identification of tumor mutation burden-related hub genes and the underlying mechanism in melanomaSemantic proximity Read ↗

Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanomaSemantic proximity Read ↗

Interplay between Tumor Mutational Burden and Mutational Profile and its effect on overall survival: A Post Hoc Analysis of Metastatic Patients Treated with Immune Checkpoint InhibitorsSemantic proximity Read ↗

Utilizes microsatellite instability characteristics for predicting the prognosis and immunotherapy sensitivity of melanoma patientsSemantic proximity Read ↗

MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study.Semantic proximity Read ↗

Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Interaction of molecular alterations with immune response in melanoma.Semantic proximity Read ↗

PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability ScoreSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.